Groups of Medications After Kidney Transplantation
Medications following kidney transplantation are generally categorized into three primary functional groups: induction therapy, maintenance immunosuppression, and prophylactic agents to prevent opportunistic infections. In addition, auxiliary medications are used to manage the long-term side effects of immunosuppression.
- Induction Therapy
Induction therapy consists of potent biological agents administered before or at the time of transplantation to provide intense early immunosuppression and prevent acute rejection.
- Interleukin-2 Receptor Antagonists (IL2-RA):
Agents such as basiliximab and daclizumab are typically used as first-line induction in patients at low immunological risk. - T-cell (Lymphocyte) Depleting Antibodies (TDAs):
Medications such as antithymocyte globulin (ATG) or alemtuzumab are recommended for high-risk recipients or as part of strategies aiming to avoid corticosteroids or calcineurin inhibitors.
- Maintenance Immunosuppression
Maintenance therapy is a long-term regimen designed to prevent graft rejection while balancing drug-specific toxicities. Standard maintenance usually involves a “triple therapy” combination.
- Calcineurin Inhibitors (CNIs):
The backbone of most regimens. Tacrolimus is generally preferred over ciclosporin due to superior prevention of acute rejection. - Anti-proliferative Agents:
These inhibit lymphocyte proliferation. Mycophenolic acid (MMF or Myfortic) is the recommended first-line agent, preferred over azathioprine. - Corticosteroids:
Usually prednisolone. High doses are used early after transplantation and tapered to a low maintenance dose (5 mg/day or less), or avoided entirely in low-risk patients who receive induction therapy. - mTOR Inhibitors (mTORi):
Sirolimus and everolimus are used as second-line agents for patients who cannot tolerate CNIs or who develop certain malignancies.
- Infection Prophylaxis
Due to the high degree of immunosuppression, recipients require medications to prevent opportunistic infections.
- Bacterial/Fungal:
Co-trimoxazole is recommended for 3–6 months to prevent Pneumocystis jirovecii (PCP) and urinary tract infections.
Clotrimazole lozenges, nystatin, or fluconazole are suggested for 1–3 months to prevent oral and esophageal Candida. - Viral:
Valganciclovir or ganciclovir is recommended for 3–6 months for cytomegalovirus (CMV) prophylaxis in at-risk recipients.
Aciclovir or valaciclovir is used to treat or prevent recurrences of HSV and VZV.
- Ancillary and Complication Management
These medications address the metabolic and systemic consequences of chronic immunosuppression.
- Cardiovascular/Blood Pressure:
ACE inhibitors or ARBs are recommended for patients with proteinuria.
Statins (such as fluvastatin) are used to manage dyslipidemia. - Bone Health:
Vitamin D, calcitriol, or bisphosphonates (e.g., pamidronate) may be used to treat transplant-related bone disease, though bisphosphonates are used cautiously due to the risk of adynamic bone disease.
• Other:
Cinacalcet is used for tertiary hyperparathyroidism.
Recombinant human growth hormone (rhGH) is recommended for persistent growth failure in pediatric recipients.
